 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...1415161718192021222324...7475» |
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
Journal: Timing of Complete Polypoidal Regression Following Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy. (Pubmed Central) - Mar 12, 2022
Most PCV eyes with complete polypoidal regression at one year already had complete regression within the first 6 months. These findings support consideration of aflibercept for PCV to achieve both anatomical and visual outcomes.
- | Avastin (bevacizumab) / Roche
Biomarker, Journal: Early predictive factors of visual loss at 1-year in neovascular age-related macular degeneration under anti-VEGF in the GEFAL study. (Pubmed Central) - Mar 11, 2022
In the present study, we found that a large CNV area at baseline was significantly associated with initial or secondary loss of visual acuity ≥5-letters despite anti-VEGF injection. The presence of fluid, both subretinal fluid (SRF) and intraretinal fluid (IRF) at M3 was found in patients with poorer trajectories.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Role of Combined Therapy of Intravitreal Ranibizumab and Dexamethasone in Refractory Diabetic Macular Edema: a Retrospective Study. (Pubmed Central) - Mar 11, 2022
Postoperatively, 21 patients out of 30 had shown encouraging results as far as both improvement in BCVA and reduction in central macular thickness (CMT) were concerned. Intravitreal Ranibizumab combined with intravitreal dexamethasone implant might be a useful tool to deal with refractory diabetic macular edema (DME).
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Multifocal Electroretinogram Alterations after Intravitreal Ranibizumab Treatment in Diabetic Macular Edema. (Pubmed Central) - Mar 11, 2022
At baseline and 6 months, the correlation between BCVA and the P1 and N1 amplitude of the central ring was significant (for baseline P1: r=-0.649, p=0.01; for N1: r=-0.575, p=0.02; for 6-month P1, r=-0.603, p<0.001; for N1: r=-0.591, p=0.005). The combination of OCT and mf-ERG can be used to evaluate the functional recovery in DME.
- | Beovu (brolucizumab-dbll) / Novartis
Biomarker, Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase III, Journal: Off label intravitreal Brolucizumab in treatment of recurrent macular edema due to branch retinal vein occlusion: A case report. (Pubmed Central) - Mar 9, 2022
Visual gains and reduction in central macular thickness were maintained with no recurrence of macular edema 2 months following the procedure. No adverse effects were noted during the entire follow up.
- | Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema (clinicaltrials.gov) - Mar 8, 2022
P3, N=42, Completed, Sponsor: Cairo University
- || Avastin (bevacizumab) / Roche
Review, Journal: Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration. (Pubmed Central) - Mar 8, 2022
The presence of a PED may be predictive of the need for more regular treatment. More well-designed studies with standardised PED definitions and classifications are needed to evaluate the relationship between PED and visual acuity.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab-The jury is still out. (Pubmed Central) - Mar 8, 2022
More well-designed studies with standardised PED definitions and classifications are needed to evaluate the relationship between PED and visual acuity. No abstract available
- || Avastin (bevacizumab) / Roche
Review, Journal: Treatment of radiation maculopathy and radiation-induced macular edema: a systematic review. (Pubmed Central) - Mar 8, 2022
Intravitreal dexamethasone implant may be an option for those with suboptimal response or contraindications to anti-VEGF agents. Possible preventive treatments that require future study are intravitreal bevacizumab and ranibizumab, peripheral laser photocoagulation, and subtenon triamcinolone acetonide.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. (Pubmed Central) - Mar 8, 2022
The incidence of lesion reactivation was highest during the first 12 months and decreased thereafter. The incidence was higher in patients with PCV than in those with neovascular AMD, especially after 12 months.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Cost and Health Care Resource Utilization (HCRU) in Patients Starting Intravitreal Dexamethasone (DEX) or ANTI-Vascular Endothelial Growth Factor (AVEGF) in Patients with Diabetic Macular Edema (DME) (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1181;
OBJECTIVES: To understand eye related HCRU and costs over two years in DME patients newly initiating treatment with DEX or aVEGF (ranibizumab-RAN, aflibercept-AFL,bevacizumab-BEV) Retrospective analysis of DME patients using IBM MarketScan database (January 1, 2015 to December 31, 2019). DEX use as initial therapy in DME was associated with significantly lower eye-related HCRU and costs compared to branded aVEGF as monotherapy and all aVEGF first combination in 12 months after initiation of therapy.
- Lucentis (ranibizumab) / Roche, Novartis
Economic Impact of Implementing Treat-and-Extend Protocol in Age-Related Macular Degeneration (AMD) in a Health Insurance Company in Brazil (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_856;
AMD is a chronic disease with significant costs in all countries, especially for developing countries with limited financial resources. The treat and extend protocol has an important impact reducing the cots allowing for better resource allocation.
- | Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Journal: Efficacy of Intravitreal Injection of Filtered Modified Low-Dose Triamcinolone Acetonide and Ranibizumab on Pseudophakic Cystoid Macular Edema. (Pubmed Central) - Mar 8, 2022
Intravitreal injection of filtered modified 2 mg TA is safe, effective, and an inexpensive alternative to antivascular endothelial growth factor (anti-VEGF) agents for patients with PCME, especially for patients concurrently with DM. A large number of clinical randomized controlled studies along with long-term follow-up observations are needed.
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation (clinicaltrials.gov) - Mar 8, 2022
P3, N=60, Recruiting, Sponsor: Affiliated Hospital of Nantong University
A large number of clinical randomized controlled studies along with long-term follow-up observations are needed. Not yet recruiting --> Recruiting
- || LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Biomarker, Clinical, Journal: Proteomic changes of aqueous humor in proliferative diabetic retinopathy patients treated with different intravitreal anti-VEGF agents. (Pubmed Central) - Mar 5, 2022
In summary, we discovered that ALDH3A1 was a previously unreported protein that was related to angiogenesis and was differentially expressed in the three anti-VEGF treatment groups, suggesting that it may be a new target for PDR therapy. The described proteomic changes in the AH of PDR patients treated with different anti-VEGF agents provide novel targets which may explain the heterogeneity of anti-VEGF treatment responses in these patients, providing a robust foundation for future studies of PDR pathogenesis.
- | nintedanib / Generic mfg.
Journal: Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells. (Pubmed Central) - Mar 5, 2022
Interestingly, the specific VEGFR2 inhibitor nintedanib normalized the lowered CI when added to iBREC pre-treated with VEGF-A for one day, but failed to do so when cells had been exposed to the growth factor for six days...To counteract these effects of VEGF-A, brolucizumab or ranibizumab was added after one day, resulting in recovery of the then lowered CI to normal values within a few hours...Taken together, barrier dysfunction induced by VEGF-A results from deregulated para- and transcellular flow but the precise nature or magnitude of underlying changes on a molecular level clearly depend on the time of exposure, evolving into a stage of VEGF-A-independent barrier impairment. These findings also provide a plausible explanation for resistance to treatment with VEGF-A antagonists frequently observed in clinical practice.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion. (Pubmed Central) - Mar 4, 2022
These findings also provide a plausible explanation for resistance to treatment with VEGF-A antagonists frequently observed in clinical practice. No abstract available
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept, Conbercept) on autophagy and its effect on neovascularization in RF/6A cells. (Pubmed Central) - Mar 4, 2022
The combination of Conbercept and autophagy inhibitor can significantly inhibit the formation of angiogenesis in vitro. The mechanism of autophagy activation is related to the activation of the p53/DRAM pathway.
- | Avastin (bevacizumab) / Roche
Journal: The Effect of Syringe Filling Technique on the Risk for Endophthalmitis after Intravitreal Injection of Anti-VEGF Agents. (Pubmed Central) - Mar 4, 2022
The syringe-filling technique is an important factor determining risk of post-injection endophthalmitis. Use of GMP-grade prefilling by professional pharmacies or the manufacturers significantly reduces this risk and should be the technique of choice for all drugs administered by intravitreal injection.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Mfsd2a overexpression alleviates vascular dysfunction in diabetic retinopathy. (Pubmed Central) - Mar 3, 2022
However, about 27% of the patients have a poor visual outcome, with 50% still having edema after two years' treatment of diabetic macular edema (DME) with ranibizumab...Moreover, Mfsd2a overexpression in combination with the DHA diet obviously reduced abnormal retinal neovascularization and vascular leakage, which is more effective than Mfsd2a overexpression alone. These results suggest that DHA therapy failure in some DR patients is linked to low expression of Mfsd2a, and the combination of Mfsd2a overexpression and DHA therapy may be an effective treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Retinal Blood Flow as a Predictor of Recurrence of Macular Edema After Intravitreal Ranibizumab Injection in Central Retinal Vein Occlusion. (Pubmed Central) - Mar 3, 2022
These results suggest that DHA therapy failure in some DR patients is linked to low expression of Mfsd2a, and the combination of Mfsd2a overexpression and DHA therapy may be an effective treatment. These findings suggest that determining %Δ MBR in LSFG may be a useful way to determine the likelihood of ME recurrence in CRVO patients.
- || Avastin (bevacizumab) / Roche
Retrospective data, Review, Journal: Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis. (Pubmed Central) - Mar 3, 2022
However, this finding is based on indirect evidence through one small trial comparing conbercept with placebo. This does not account for drug-specific differences when assessing anatomic and functional treatment efficacy in variable dosing regimens.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Assessment of choriocapillaris/Sattler and Haller layer changes after intravitreal injection in eyes with neovascular age-related macular degeneration: aflibercept vs ranibizumab. (Pubmed Central) - Mar 3, 2022
Aflibercept treatment has a more pronounced effect on the CC/Sattler layer. Such results may indicate that aflibercept treatment influences choroidal neovascularization, possibly by reducing the capillary permeability associated with active neovascularization in the CC layer.
- | Avastin (bevacizumab) / Roche
Journal: Monoclonal antibodies in diabetic retinopathy. (Pubmed Central) - Mar 3, 2022
Relevant clinical studies were imported. Future direction includes detection of more therapeutic targets considering other components of DR pathophysiology and shared pathogenesis of DR and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, the treat-and-extend regimen, and new ways of drug delivery and other routes of ocular drug administration.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study. (Pubmed Central) - Mar 3, 2022
The eyes with CME secondary to DR have a higher percentage of progressed HEs than the BRVO eyes. DME with SRF, extended duration of CME, and high LDL-C level are potential risk factors of deteriorated HEs after IVR treatment.
- || Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Phase classification, Trial completion date, Trial primary completion date: Belvedere: A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (clinicaltrials.gov) - Mar 3, 2022
P4, N=200, Recruiting, Sponsor: Genentech, Inc.
DME with SRF, extended duration of CME, and high LDL-C level are potential risk factors of deteriorated HEs after IVR treatment. Phase classification: P3b/4 --> P4 | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: May 2023 --> Jan 2024
- Trial completion date, Trial primary completion date: STAMP: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification (clinicaltrials.gov) - Mar 2, 2022
P4, N=32, Recruiting, Sponsor: Bay Area Retina Associates
Phase classification: P3b/4 --> P4 | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: May 2023 --> Jan 2024 Trial completion date: Oct 2020 --> Oct 2022 | Trial primary completion date: Jun 2020 --> Jul 2022
- | Avastin (bevacizumab) / Roche
Journal: DRIL INFLUENCES SHORT-TERM VISUAL OUTCOME AFTER INTRAVITREAL CORTICOSTEROID INJECTION FOR REFRACTORY DIABETIC MACULAR EDEMA. (Pubmed Central) - Mar 1, 2022
: Subfoveal DRIL on structural OCT was the DME factor influencing significantly clinical and imaging outcomes in refractory DME patients treated with intravitreal corticosteroid. Portuguese care trend towards DME shows preference for the use of dexamethasone implant after therapeutic failure with ranibizumab or bevacizumab injection.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Journal: Evaluation of the effects of intravitreal aflibercept and ranibizumab on systemic inflammatory and cardiovascular biomarkers in patients with neovascular age-related macular degeneration. (Pubmed Central) - Mar 1, 2022
Also, there was no significant change in fibrinogen, lymphocyte count, MLR, HDL-c, UA, PLR, and platelet count values in both groups. Compared to IVR, IVA treatment had a small but significant effect on systemic inflammatory and cardiovascular biomarkers.
- | Avastin (bevacizumab) / Roche
Journal: Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period. (Pubmed Central) - Mar 1, 2022
The incidence of endophthalmitis after intravitreal injection decreased and visual outcomes improved between the periods of 2009-2012 and 2016-2017. A "no-talking" policy during injections was associated with a trend toward a decrease in endophthalmitis rate.
- || LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Journal: Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study. (Pubmed Central) - Mar 1, 2022
Less frequent dispensations and surveillance examinations were observed than in monthly schemes applied in registration trials for IVT anti-VEGF. These results may indicate a lack of systematic monitoring associated with fewer injections and/or clinicians' preference for more flexible and personalized injection schemes than those originally recommended.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron
Reimbursement, Retrospective data, Journal: Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan. (Pubmed Central) - Mar 1, 2022
Eyes receiving aflibercept required less supplementary PRP and SMPL treatment than those receiving ranibizumab. The initial VA influenced the final VA improvements at 24 months, while age and initial CRT were prognostic predictors of 24-month CRT reduction.
- | Avastin (bevacizumab) / Roche
Journal: Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice. (Pubmed Central) - Feb 27, 2022
The initial VA influenced the final VA improvements at 24 months, while age and initial CRT were prognostic predictors of 24-month CRT reduction. Fixed q8 ranibizumab, q8 bevacizumab, q12 aflibercept, or q10 brolucizumab regimens may produce adequate intraocular VEGF inhibition.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial. (Pubmed Central) - Feb 27, 2022
P4
Fixed q8 ranibizumab, q8 bevacizumab, q12 aflibercept, or q10 brolucizumab regimens may produce adequate intraocular VEGF inhibition. EMB does not reduce the number of anti-vascular endothelial growth factor (VEGF) injections, either within or outside of a trial setting, and is associated with worse BCVA than anti-VEGF monotherapy.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Systemic Immunosuppression Is Highly Effective in the Long-term Control of Inflammatory non-infectious Uveitic Choroidal Neovascularization: A Comparative Study. (Pubmed Central) - Feb 26, 2022
Both groups received systemic steroids and intravitreal ranibizumab since baseline...In the long term, best-corrected visual acuity (BCVA) was significantly better in group B. At 3-month follow-up, Group B reduced steroids <10 mg/day significantly (p = .0001, Fisher's Exact Test). At 36 months of follow up, injections given were 2.9 (0.9 SD) in group A and 1.25 (0.4 SD) in group B. early immunosuppressive therapy exerts a positive action on the long-term control of uveitic CNV.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Herpetic Keratouveitis following Intravitreal Ranibizumab Injection in a Case with Diabetic Macular Edema. (Pubmed Central) - Feb 26, 2022
Herpetic keratouveitis can be seen as a rare complication of intravitreal ranibizumab injection. To our best knowledge, this is the first case with herpes keratouveitis developed following intravitreal ranibizumab injection.
- | Avastin (bevacizumab) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Anti-Vascular Endothelial Growth Factor Drug Conbercept-Loaded Peptide Hydrogel Reduced Angiogenesis in the Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Feb 26, 2022
The In vitro experiments showed that either dose-dependent or the time-dependent incubation with peptide would not decrease the cell viability of HREC, revealing that the peptide was biocompatible. The most important is that co-incubation with HREC obviously reduced the HREC proliferation and tube formation induced by VEGF, ensuring its potential for the treatment efficacy of nAMD.
- | Avastin (bevacizumab) / Roche
Journal: Mid-Term Impact of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure. (Pubmed Central) - Feb 26, 2022
Ranibizumab was associated with a higher rate of increase in clinically significant IOP at 6 months (p = 0.03). Our study confirms that anti-VEGF injections constitute a relatively safe treatment regarding their impact on IOP.
- | Beovu (brolucizumab-dbll) / Novartis, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Pricing, Journal: Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases. (Pubmed Central) - Feb 26, 2022
We propose mechanisms for anticipating and facilitating the market introduction of biosimilars, as well as changes to the pricing model in Medicare that can promote use of cost-effective therapies. Reforms such as empowering Medicare to negotiate drug prices may help ensure that introduction of new biologics and biosimilars for AMD will lower spending and increase patient access.
- | Lucentis (ranibizumab) / Roche, Novartis
Preclinical, Journal: Effects of ranibizumab and zoledronic acid on endometriosis in a rat model. (Pubmed Central) - Feb 26, 2022
Reforms such as empowering Medicare to negotiate drug prices may help ensure that introduction of new biologics and biosimilars for AMD will lower spending and increase patient access. No abstract available
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Real-world evidence: Real-world incidence of endophthalmitis after intravitreal anti-VEGF injection: Common Data Model in ophthalmology. (Pubmed Central) - Feb 25, 2022
The off-label use of bevacizumab accounted for its disproportionately high incidence of endophthalmitis. The OMOP CDM, which includes off-label uses, laboratory data, and a scalable standardized database, could provide a novel strategy to reveal real-world evidence, especially in ophthalmology.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Effects of the Presence of Pseudoexfoliation on Intraocular Pressure and Retinal Nerve Fiber Layer Thickness in Patients with Macular Degeneration Receiving Intravitreal Ranibizumab. (Pubmed Central) - Feb 25, 2022
Ranibizumab may reduce RNFL thickness in patients with PEX. Longer-term studies including larger populations are necessary for understanding IOP and RNFL changes after anti-vascular endothelial growth factor (anti-VEGF) injection.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Creation of retinal vein occlusion model in cynomolgusmonkeys and determination of its pathological features. (Pubmed Central) - Feb 24, 2022
In this model, an injection of ranibizumab leads to a reduction in the vascular leakage and the retinal thickness and volume by blockingthe expression of VEGF. Our model might be useful for investigating the pathological mechanisms of RVOs and explore new therapeutic agents for RVO.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Combination therapy: Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study. (Pubmed Central) - Feb 22, 2022
Discontinuation of ranibizumab treatment in PDR patients may result in an increase of NV area and VA loss. Tight monitoring of disease activity and continued treatment beyond the first year is needed to maintain disease control.
- | Lucentis (ranibizumab) / Roche, Novartis
New P1 trial: A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy (clinicaltrials.gov) - Feb 20, 2022
P1, N=120, Recruiting, Sponsor: Tianjin Medical University Eye Hospital
- || FYB201 (ranibizumab biosimilar) / Amneal, Formycon, Coherus Biosci, Teva, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Feb 19, 2022
Tight monitoring of disease activity and continued treatment beyond the first year is needed to maintain disease control. FYB201 is biosimilar to reference ranibizumab in terms of clinical efficacy and ocular and systemic safety in the treatment of patients with nAMD.
- | Avastin (bevacizumab) / Roche
Journal: Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. (Pubmed Central) - Feb 19, 2022
Further evidence is required to assess the comparative efficacy of these therapies. Given the limited high-quality comparative efficacy data, choice of therapy must be individualized for each patient and broad therapeutic access for patients is critical to maximize outcomes.
- | Avastin (bevacizumab) / Roche
Journal: Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. (Pubmed Central) - Feb 19, 2022
Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Disease-modifying effects of ranibizumab for central retinal vein occlusion. (Pubmed Central) - Feb 19, 2022
Ranibizumab for CRVO resulted in beneficial disease-modifying effects through a reduction in retinal hemorrhage, neovascularization, and papillary swelling. These findings may form the basis for future work in the development of a treatment response or severity scale for eyes with CRVO.
- | Beovu (brolucizumab-dbll) / Novartis
Journal: Bilateral blindness after uneventful brolucizumab injection for macular degeneration. (Pubmed Central) - Feb 19, 2022
We do not recommend performing bilateral brolucizumab injections until more data is available regarding the mechanism of brolucizumab-induced vasculitis. From a clinical point of view, we find it difficult to justify the use of brolucizumab when there are other well-known agents, such as ranibizumab and aflibercept, which have better safety profiles and comparable efficacy.